Literature DB >> 190609

Gemfibrozil treatment: a comparison with clofibrate.

A N Howard, P Ghosh.   

Abstract

Gemfibrozil was found to be an effective hypotriglyceridaemic agent in types IV, IIb and V hyperlipoproteinaemia. When given at a dose level of 800 mg/day its activity was nearly of the same order of magnitude as 1.5 g/day of clofibrate.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 190609      PMCID: PMC1864044     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


  4 in total

1.  Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man.

Authors:  D Pertsemlidis; D Panveliwalla; E H Ahrens
Journal:  Gastroenterology       Date:  1974-04       Impact factor: 22.682

2.  Comparison of membrane filtration and nephelometry with analytical ultracentrifugation, for the quantitative analysis of low density lipoprotein fractions.

Authors:  M C Stone; J M Thorp; G L Mills; T B Dick
Journal:  Clin Chim Acta       Date:  1970-12       Impact factor: 3.786

3.  Letter: Clofibrate and gallstones.

Authors:  J Cooper; H Geizerova; M F Oliver
Journal:  Lancet       Date:  1975-05-10       Impact factor: 79.321

4.  Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat.

Authors:  R Hess; W Stäubli; W Riess
Journal:  Nature       Date:  1965-11-27       Impact factor: 49.962

  4 in total
  1 in total

Review 1.  Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.

Authors:  P A Todd; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.